InvestorsHub Logo
Followers 91
Posts 5592
Boards Moderated 0
Alias Born 06/05/2008

Re: None

Thursday, 12/03/2020 7:10:44 PM

Thursday, December 03, 2020 7:10:44 PM

Post# of 2145
Bonus: Stroke prevention:

Hepion Pharmaceuticals (NASDAQ:HEPA) has announced results from a translational research study in which its lead drug candidate, CRV431 decreased formation of a class of blood platelets, called ‘procoagulant platelets, and high levels of such platelets are associated with transient ischemic attack and stroke. (Dec. 02, 2020 8:37 AM ETHepion Pharmaceuticals, Inc. (HEPA)By: Meghavi Singh, SA News Editor)

Non-Bonus: Big D = Share Dilution, but not as bad as many penny stocks.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News